Evidence map›Paper›PMID 39013135›Full record

ArticleJCO precision oncology2024

Transcriptomic Profiling of Primary Prostate Cancers and Nonlocalized Disease on Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography: A Multicenter Retrospective Study.

John Nikitas, Kritika Subramanian, Nimrod Barashi Gozal, Andres Ricaurte-Fajardo, Eric Li, James A Proudfoot, Elai Davicioni, Ariel E Marciscano, Joseph R Osborne, Christopher E Barbieri and 15 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in JCO precision oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

25 authors.

John NikitasDepartment of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA.ORCID 0000-0002-1101-7233
Kritika SubramanianDepartment of Nuclear Medicine, New York-Presbyterian/Weill Cornell Hospital, New York, NY.
Nimrod Barashi GozalDivision of Urologic Surgery, Washington University School of Medicine, St Louis, MO.
Andres Ricaurte-FajardoDepartment of Radiology, New York-Presbyterian/Weill Cornell Hospital, New York, NY.ORCID 0000-0002-7374-4460
Eric LiDepartment of Urology, Northwestern University, Feinberg School of Medicine, Chicago, IL.ORCID 0000-0002-5506-5755
James A ProudfootVeracyte Inc, San Diego, CA.
Elai DavicioniVeracyte Inc, San Diego, CA.ORCID 0000-0001-9136-099X
Ariel E MarciscanoDepartment of Radiation Oncology, New York-Presbyterian Hospital/Weill Cornell Medical College, New York, NY.ORCID 0000-0001-8838-2127
Joseph R OsborneDepartment of Radiology, New York-Presbyterian/Weill Cornell Hospital, New York, NY.ORCID 0000-0003-0232-5960
Christopher E BarbieriDepartment of Urology, New York-Presbyterian/Weill Cornell Medical Center, New York, NY.ORCID 0000-0002-0381-1947
Wesley R ArmstrongAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA.ORCID 0000-0002-9168-8511
Clayton P SmithDepartment of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA.ORCID 0000-0002-8509-6237
Luca F ValleDepartment of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA.ORCID 0000-0002-5781-4174
Michael L SteinbergDepartment of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA.ORCID 0000-0002-4292-5824
Paul C BoutrosDepartment of Urology, University of California, Los Angeles, Los Angeles, CA.ORCID 0000-0003-0553-7520
Nicholas G NickolsDepartment of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA.
Matthew B RettigDepartments of Medicine and Urology, University of California, Los Angeles, Los Angeles, CA.ORCID 0000-0002-7394-3056
Robert ReiterDepartment of Urology, University of California, Los Angeles, Los Angeles, CA.ORCID 0000-0002-2654-1628
Adam B WeinerDepartment of Urology, University of California, Los Angeles, Los Angeles, CA.
Jeremie CalaisAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA.ORCID 0000-0002-8839-4379
Johannes CzerninAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA.
Ashley Evan RossDepartment of Urology, Northwestern University, Feinberg School of Medicine, Chicago, IL.ORCID 0000-0001-7044-9688
Eric H KimDivision of Urology, Department of Surgery, University of Nevada Reno School of Medicine, Reno, NV.ORCID 0000-0002-0284-8342
Himanshu NagarDepartment of Radiation Oncology, New York-Presbyterian Hospital/Weill Cornell Medical College, New York, NY.
Amar U KishanDepartment of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA.ORCID 0000-0002-7437-6591

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
UCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Yvonne Yu-Hsuan Chen · 2017 to 2026
$25.2M
Integrative Cancer Scholars Training GrantT32CA009213 · NCI · UNIVERSITY OF ARIZONA · PI CAREW, JENNIFER S, CURIEL-LEWANDROWSKI, CLARA · 1985 to 2024
$8.6M
Reducing toxicity from prostate cancer radiotherapy through genetics and technologyR37CA292795 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Amar U Kishan · 2024 to 2026
$1.1M
NCI NIH HHS P30 CA016042NCI NIH HHS P50 CA211015NCI NIH HHS R37 CA292795NCI NIH HHS T32 CA009213
6 · The paper itself

Abstract

purposeTo characterize the relationship between Decipher genomic classifier scores and prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT)-based metastatic spread. MATERIALS AND

methodsWe identified patients from four institutions who underwent PSMA PET/CT scans pretreatment for primary staging or postradical prostatectomy (RP) for suspected recurrence and had Decipher transcriptomic data available from biopsy or RP specimens. PSMA PET/CT-based patterns of spread were classified as localized (miT + N0M0) or nonlocalized (miN1M0 or miM1a-c). We calculated the association between Decipher scores and the risk of nonlocalized disease on PSMA PET/CT using multivariable logistic regression for pretreatment patients and multivariable Cox regression for post-RP patients. We also compared select transcriptomic signatures between patients with localized and nonlocalized diseases.

resultsFive hundred eighty-six patients were included (pretreatment: n = 329; post-RP: n = 257). Higher Decipher scores were associated with nonlocalized disease on PSMA PET/CT both pretreatment (odds ratio, 1.18 [95% CI, 1.03 to 1.36] per 0.1 increase in Decipher score,

conclusionHigher Decipher scores were associated with nonlocalized disease identified on PSMA PET/CT both pretreatment and post-RP. There were several transcriptomic differences between localized and nonlocalized diseases in both settings.

Indexed as

Gene Expression ProfilingPositron Emission Tomography Computed TomographyProstatic NeoplasmsAgedAntigens, SurfaceGlutamate Carboxypeptidase IIHumansMaleMiddle AgedRetrospective StudiesTranscriptomeAntigens, SurfaceFOLH1 protein, humanGlutamate Carboxypeptidase II

Identifiers

PMID39013135
PMCPMC11770880

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.